参七散剂治疗非酒精性脂肪性肝病的临床研究

Clinical efficacy of Shenqi Powder in treatment of non-alcoholic fatty liver disease

目的:观察参七散剂对非酒精性脂肪肝(NAFLD)患者转氨酶水平、血脂水平及肝脏超声学指标的影响,评价其临床疗效。方法:将50例NAFLD患者随机分成对照组和治疗组各25例,治疗组给予参七散剂口服治疗,对照组给予易善复口服治疗,两组疗程均为2个月。治疗前后分别进行血脂4项、谷氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)和肝脏超声学指标检测。结果:两组均能降低TC、TG、LDL-C、ALT、AST水平,升高HDL-C水平,且改善程度治疗组均优于对照组,差异均有统计学意义(P<0.01);与对照组比较,治疗组减轻肝细胞脂肪变性程度疗效更显著,差异有统计学意义(P<0.05);总有效率治疗组为88.0%,对照组为76.0%,两组比较,差异有统计学意义(P<0.01)。结论:参七散剂对NAFLD有较好的疗效。

Objective： To investigate the clinical effects of Shenqi Powder on the levels of transaminases and blood lipid and liver ultrasound indicators in patients with non - alcoholic fatty liver disease （NAFLD）. Methods ： A total of 50 NAFLD patients were randomly and equally divided into control group （ n = 25 ） and treatment group （ n = 25）. The treatment group and control group were orally administered Shenqi Powder and Essentiale, respective- ly. Both groups were treated for two months. The four items of blood lipid test, alanine transaminase（ALT） , aspartate transaminase （AST）, and liver ultrasound indicators of the two groups were determined before and after treatment. Results ： Both groups showed reduced levels of total cholesterol, triglyceride, low - density lipoprotein cho- lesterol, ALT, and AST and an increased level of high - density lipoprotein cholesterol, and the treatment group showed significantly more improvements than the control group（P 〈0. 01 ）. The treatment group also showed a significantly better clinical effect in alleviating hepatic steatosis than the control group （P 〈 0. 05 ）. The overall response rates of the treatment group and control group were 88.0% and 76. 0%, respectively, and the difference was significant （P 〈 0. 01 ）. Conclusion ： Shenqi powder has good clinical efficacy in the treatment of NAFLD.